1 citations
,
December 2005 in “The Journal of Urology” Combination therapy for BPH is more effective in certain men but may not be cost-effective due to minimal impact and potential side effects.
March 2014 in “Annals of Internal Medicine” Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.
1 citations
,
March 2022 in “British Journal of Clinical Pharmacology” 5α-reductase inhibitors do not increase anaemia risk compared to α-blockers in men with BPH.
6 citations
,
August 2021 in “Clinical Epidemiology” Men using 5-alpha reductase inhibitors for prostate issues may have a slightly higher risk of blood clots.
2 citations
,
May 2023 in “Al Mustansiriyah Journal of Pharmaceutical Sciences” Pterostilbene significantly reduces prostate enlargement and has strong antioxidant effects.
August 2019 in “KMOU Repository (Korea Maritime and Ocean University)” Sapium rotundifolium extract may help treat enlarged prostate.
38 citations
,
January 2005 in “PubMed” Dutasteride effectively treats enlarged prostate with manageable side effects.
2 citations
,
January 2011 in “Clinical medicine insights” Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
Endurance exercise may help BPH by lowering hormones and inflammation.
2 citations
,
September 2011 in “Der Urologe” Prostate cancer prevention now focuses on healthy diets and some medications, not vitamins.
February 2004 in “Oncology Times” Green tea extract and cycling hormone treatments may help treat advanced prostate cancer.
3 citations
,
January 2023 in “Clinical cancer investigation journal” Some cannabinoid derivatives may be more effective than current drugs at targeting proteins relevant to prostate cancer treatment.
September 2011 in “Urology” Biofeedback treatment for dysfunctional voiding in adults showed no symptom improvement.
July 2004 in “Current Urology Reports” 11 citations
,
June 2020 in “Biomedicines” % free PSA and urinary markers help better identify prostate cancer.
The role of 5α-reductase-3 in prostate cancer is unclear and needs more research.
Bilateral Orchiectomy effectively reduces the need for anti-androgen medication in most transgender females.
1 citations
,
March 2005 in “Zentralblatt für Gynäkologie” A postmenopausal woman had high testosterone from her right adrenal gland, leading to recommended surgery.
January 2004 in “Anticancer Research” Long-term antiandrogen use may increase aggressive prostate cancer risk.
29 citations
,
July 2012 in “The Journal of Sexual Medicine” Rats had lasting erectile problems after stopping a certain medication.
March 2005 in “The Nurse Practitioner”
8 citations
,
February 2021 in “Journal of the American Heart Association” Medical castration in prostate cancer patients can increase the risk of serious heart rhythm problems, so it's important to monitor heart activity during treatment.
March 2026 in “Journal of the American Academy of Dermatology”
5 citations
,
August 2005 in “Current Urology Reports” Saw palmetto helps with nighttime urination and urine flow, similar to finasteride.
October 2025 in “Pakistan journal of urology.” Personalized, minimally invasive treatments improve urology outcomes.
57 citations
,
April 2009 in “The Journal of Steroid Biochemistry and Molecular Biology” Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.
August 2025 in “Therapeutics” Low-dose DMSO may help treat castration-resistant prostate cancer by reducing key cancer cell receptors.
January 2026 in “Journal of Pharmacy & Bioresources” Many patients with benign prostatic hyperplasia experience high anxiety and residual symptoms, needing better anxiety management.
March 2026 in “Journal of Multidisciplinary Applied Natural Science” Cosmos caudatus extract is as effective as finasteride for treating benign prostatic hyperplasia without its side effects.
402 citations
,
August 2011 in “Cancer research” Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.